During the corresponding time, Organon And Co saw a revenue deteriorated by -2.26 % year on year, sequentially revenue grew by 6.71 %. While revenue at the Organon And Co 's corporate clients
Organon And Co's Comment on Sales, Marketing and Customers
The company provides services to healthcare providers, patients, and payors through customer engagement strategies across multiple channels, including face-to-face interactions, virtual platforms, email, social media, and websites. Its products are distributed globally to patients in over 140 countries via regional distribution centers and partnerships. Customers include drug wholesalers and retailers, hospitals, clinics, government agencies, pharmacies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. The company also utilizes third-party distributors and agents for smaller markets. Professional representatives communicate product information to healthcare professionals in private practice, group practices, hospitals, and managed care organizations. The company operates six manufacturing sites focused on various therapeutic areas and manufactures products for third parties, including Merck & Co., Inc., under contract manufacturing agreements.
In a significant development for the pharmaceutical sector, the European Commission (EC) has granted market authorization for BILDYOS and BILPREVDA, two biosimilar versions of Denosumab sourced from Henlius Biotech, Inc. and Organon. These approvals open up new avenues for treatment in various medical indications previously dominated by the original products, PROLIA and XGEVA, which are widely used in conditions such as osteoporosis and bone loss. Regulatory Approval HighlightsThe approval of BILDYOS (Denosumab) 60 mg/ml injection and BILPREVDA (Denosumab) 120 mg/1.7 ml injection signifies the culmination of extensive clinical trials and regulatory scrutiny. The EC s endorsement allows these biosimilars to c...
Henlius and Organon Take Significant Leap in Oncology with EMA Validation of Biosimilar HLX11 for HER2-Positive Breast Cancer In a significant development for oncology therapeutics, the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) from Shanghai Henlius Biotech, Inc. and Organon for HLX11, an investigational biosimilar of pertuzumab (marketed as Perjeta). This pivotal acknowledgment marks a critical step forward in addressing the substantial medical need for effective treatments for HER2-positive breast cancer patients. Originally approved in multiple regions worldwide, pertuzumab has revolutionized the neoadjuvant treatment approach for patients diagnosed with l...
In a strategic move to enhance its market presence in the area of migraine treatment, Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, has announced the expansion of its commercial agreement with Eli Lilly and Company. As part of this agreement, Organon will become the exclusive distributor and promoter of Emgality (galcanezumab), a medication used for the prevention of migraine, in eleven additional markets. These markets include Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey, and the United Arab Emirates.The expansion comes at a time when Organon faces mounting financial challenges. Recent financial reports indicate that the comp...
: Organon, a global healthcare company focused on women s health, is expanding its market presence through strategic partnerships and regulatory breakthroughs. Recently, it has broadened its commercialization agreement with Eli Lilly and Company for the migraine treatment Emgality (galcanezumab) to eleven additional markets. Furthermore, the company has achieved a significant milestone with the European Medicines Agency (EMA) validating the marketing authorization applications for HLX14, a biosimilar candidate to Prolia and Xgeva (denosumab), developed in collaboration with Shanghai Henlius Biotech, Inc. This article examines these developments and their implications for Organon’s market position and gro...
: The European Medicines Agency (EMA) has validated the Marketing Authorization Applications (MAAs) for HLX14, a biosimilar of denosumab, used under the brand names Prolia and Xgeva, developed by Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN). The approval seeks to broaden the accessibility of denosumab, which is already sanctioned under various commercial names in multiple countries for different indications. Despite this biotechnological advancement, Organon and Co. have experienced a revenue decline of -1.17% year-over-year and a sequential reduction of -5.53%. The journey towards offering more affordable biologic therapies has taken a significant step forward with the European Medicin...
EMA Validates Marketing Authorization Applications for Henlius and Organon s Biosimilar Candidate to Prolia and Xgeva Shanghai, China and Jersey City, N.J. Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have announced a significant step in their collaborative effort to introduce a biosimilar candidate to the market. The European Medicines Agency (EMA) has validated their marketing authorization applications (MAAs) for HLX14, a biologically equivalent investigational drug to Prolia and Xgeva (denosumab). Denosumab: A Multifaceted Therapeutic AgentDenosumab, a RANKL (receptor activator of nuclear factor kappa-? ligand) inhibitor, is recognized and approved across various countries and reg...
Organon And Co’s Comment on Sales, Marketing and Customers
The company provides services to healthcare providers, patients, and payors through customer engagement strategies across multiple channels, including face-to-face interactions, virtual platforms, email, social media, and websites. Its products are distributed globally to patients in over 140 countries via regional distribution centers and partnerships. Customers include drug wholesalers and retailers, hospitals, clinics, government agencies, pharmacies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. The company also utilizes third-party distributors and agents for smaller markets. Professional representatives communicate product information to healthcare professionals in private practice, group practices, hospitals, and managed care organizations. The company operates six manufacturing sites focused on various therapeutic areas and manufactures products for third parties, including Merck & Co., Inc., under contract manufacturing agreements.
Sources:
Organon and Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Organon and Co’s corporate clients.
For your research, we’ve provided 9 tables on Organon and Co corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.77 %